Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare J Fowler

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
European Urology|October 12, 2010
Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysisThomas M Kessler, David La Framboise, Sven Trelle, et al.
Journal of the American Geriatrics Society|December 13, 2012
White matter lesions or Alzheimer's disease: which contributes more to overactive bladder and incontinence in elderly adults with dementia?Osamu Takahashi, Ryuji Sakakibara, Jalesh Panicker, et al.
European Urology|October 1, 2008
Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus reportApostolos Apostolidis, Prokar Dasgupta, Pierre Denys, et al.
European Urology|April 3, 2012
OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trialClare J Fowler, Stephen Auerbach, David Ginsberg, et al.
The Journal of Urology|February 24, 2009
What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injectionShahid Khan, Thomas M Kessler, Apostolos Apostolidis, et al.
The Journal of Urology|February 22, 2011
Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosisShahid Khan, Xavier Game, Vinay Kalsi, et al.
European Urology|January 18, 2006
Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centreVinay Kalsi, Roshni B Popat, Apostolos Apostolidis, et al.
European Urology|March 18, 2008
Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivityApostolos Apostolidis, Thomas S Jacques, Alex Freeman, et al.
European Urology|December 5, 2008
Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatmentAlexander Roosen, Soumendra N Datta, Rasheda A Chowdhury, et al.
The Journal of Urology|September 18, 2007
Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical studyPhilip E V van Kerrebroeck, Anco C van Voskuilen, John P F A Heesakkers, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
European Urology|October 12, 2010
Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysisThomas M Kessler, David La Framboise, Sven Trelle, et al.
Journal of the American Geriatrics Society|December 13, 2012
White matter lesions or Alzheimer's disease: which contributes more to overactive bladder and incontinence in elderly adults with dementia?Osamu Takahashi, Ryuji Sakakibara, Jalesh Panicker, et al.
European Urology|October 1, 2008
Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus reportApostolos Apostolidis, Prokar Dasgupta, Pierre Denys, et al.
European Urology|April 3, 2012
OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trialClare J Fowler, Stephen Auerbach, David Ginsberg, et al.
The Journal of Urology|February 24, 2009
What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injectionShahid Khan, Thomas M Kessler, Apostolos Apostolidis, et al.
The Journal of Urology|February 22, 2011
Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosisShahid Khan, Xavier Game, Vinay Kalsi, et al.
European Urology|January 18, 2006
Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centreVinay Kalsi, Roshni B Popat, Apostolos Apostolidis, et al.
European Urology|March 18, 2008
Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivityApostolos Apostolidis, Thomas S Jacques, Alex Freeman, et al.
European Urology|December 5, 2008
Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatmentAlexander Roosen, Soumendra N Datta, Rasheda A Chowdhury, et al.
The Journal of Urology|September 18, 2007
Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical studyPhilip E V van Kerrebroeck, Anco C van Voskuilen, John P F A Heesakkers, et al.
Pageof 10